Interstitial Lung DiseaseOxidative Stress

Efficacy and Safety of Hydrogen Therapy in Patients with Early-Stage Interstitial Lung Disease: A Single-Center, Randomized, Parallel-Group Controlled Trial

by Chang Tang, Chenggong Guan, Fanping Yang, Haiqing Gao, Jin Yang, Lanting Wang, Li Ma, Lin Tang, Qiaozhi Gu, Shan He, Shengan Chen, Xiaoqun Luo, Ying Zhao, Yu Xu, Zhen Zhang, Zihua Chen

Abstract:

Purpose: Several in vivo experiments have shown that molecular hydrogen is a promising therapeutic agent for interstitial lung diseases (ILD). In this study, hydrogen therapy was investigated to determine whether it is superior to N-Acetylcysteine (NAC) for the treatment of patients with early-stage ILD. Patients and methods: A prospective, single-center, randomized, controlled clinical trial was conducted in 87 patients with early-stage ILD. Hydrogen or NAC therapy was randomly assigned (1:1 ratio) to the eligible patients. The primary endpoint was the change in the high-resolution computed tomography (HRCT) and composite physiologic index (CPI) scores from baseline to week 48. Pulmonary function was evaluated as a secondary endpoint, and adverse events were recorded for safety analysis. Results: The rate of HRCT image improvement from the baseline in the HW group (63.6%) was higher than that in the NAC group (39.5%). A significant decrease in CPI and improvement in DLCO-sb were observed in the hydrogen group compared with those in the control group. Changes in other pulmonary function parameters, including FVC, FEV1, FEV1/FVC%, and TLC, were not significantly different between the two groups. Adverse events were reported in 7 (15.9%) patients in the HW group and 10 (23.3%) patients in the NAC group, but the difference was not significant (P=0.706). Conclusion: Hydrogen therapy exhibits superior efficacy and acceptable safety compared with NAC therapy in patients with early-stage ILD.


Read more:

https://doi.org/10.2147/TCRM.S438044


Related Articles:

ROS-responsive magnesium-containing microspheres for antioxidative treatment of intervertebral disc degeneration

Intervertebral disc degeneration (IVDD) is a degenerative disease characterized by lower-back pain, causing disability globally. Antioxidant therapy is currently considered one of the most promising strategies for IVDD treatment, given the crucial role of reactive oxygen species (ROS) in IVDD...

Year Published: 2023SpineIntervertebral Disc DegenerationPositive
High Concentration Hydrogen Mitigates Sepsis-Induced Acute Lung Injury in Mice by Alleviating...

Background: Multiple organ failure (MOF) is the main cause of early death in septic shock. Lungs are among the organs that are affected in MOF, resulting in acute lung injury. A large number of inflammatory factors and stress injury in...

Year Published: 2023LungSepsisPositive
Effectiveness and safety of hydrogen inhalation as an adjunct treatment in Chinese...

Aim: To analyze the effectiveness and safety of hydrogen inhalation (HI) therapy as an adjunct treatment in Chinese type 2 diabetes mellitus (T2DM) patients in a real-life clinical setting. Methods: This observational, non-interventional, retrospective, double-arm, 6-month clinical study included T2DM...

Year Published: 2023Whole BodyDiabetes (Type II)Positive
Hydrogen inhalation attenuates lung contusion after blunt chest trauma in mice

Background: Lung contusion caused by blunt chest trauma evokes a severe inflammatory reaction in the pulmonary parenchyma that may be associated with acute respiratory distress syndrome. Although hydrogen gas has antioxidant and anti-inflammatory effects and is protective against multiple types...

Year Published: 2023LungBlunt Chest TraumaPositive